Crosslink (Drug Discovery) Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.5M
- Investors
-
5
Crosslink (Drug Discovery) General Information
Description
Operator of a biologics platform designed to improve tumor-specific targeting and enhance activity. The company's technology utilizes a modular biologic domain that conditionally assembles therapeutics in the tumor microenvironment by taking advantage of elevated extracellular ATP, enabling oncology researchers and pharmaceutical developers to achieve improved tumor targeting and therapeutic effectiveness.
Contact Information
Website
www.xlinktx.comCorporate Office
- 349-351 Newbury Street
- Boston, MA 02115
- United States
Corporate Office
- 349-351 Newbury Street
- Boston, MA 02115
- United States
Crosslink (Drug Discovery) Timeline
Crosslink (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 20-Oct-2026 | $5.5M | Completed | Startup | ||
| 1. Seed Round | 25-Apr-2025 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Crosslink (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Crosslink (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Crosslink (Drug Discovery) Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cure Ventures | Venture Capital | Minority | ||
| Highlight Capital | Venture Capital | Minority | ||
| Rivas Capital | Venture Capital | Minority | ||
| Sigmas Group | Asset Manager | |||
| TIFF Investment Management | Limited Partner |
Crosslink (Drug Discovery) FAQs
-
When was Crosslink (Drug Discovery) founded?
Crosslink (Drug Discovery) was founded in 2021.
-
Where is Crosslink (Drug Discovery) headquartered?
Crosslink (Drug Discovery) is headquartered in Boston, MA.
-
What is the size of Crosslink (Drug Discovery)?
Crosslink (Drug Discovery) has 4 total employees.
-
What industry is Crosslink (Drug Discovery) in?
Crosslink (Drug Discovery)’s primary industry is Biotechnology.
-
Is Crosslink (Drug Discovery) a private or public company?
Crosslink (Drug Discovery) is a Private company.
-
What is Crosslink (Drug Discovery)’s current revenue?
The current revenue for Crosslink (Drug Discovery) is .
-
How much funding has Crosslink (Drug Discovery) raised over time?
Crosslink (Drug Discovery) has raised $13.5M.
-
Who are Crosslink (Drug Discovery)’s investors?
Cure Ventures, Highlight Capital, Rivas Capital, Sigmas Group, and TIFF Investment Management have invested in Crosslink (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
